P-glycoprotein (P-gp)-mediated efflux limits intestinal absorption of the Hsp90 inhibitor SNX-2112 in rats

References

• Aller SG, Yu J, Ward A, et al. (2009). Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718–22
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413–20
   PubMed Web of Science ®Google Scholar
• Amin ML. (2013). P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7:27–34
   PubMedGoogle Scholar
• Bellamy WT. (1996). P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol 36:161–83
   PubMed Web of Science ®Google Scholar
• Benet LZ, Cummins CL, Wu CY. (2004). Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 277:3–9
   PubMed Web of Science ®Google Scholar
• Breedveld P, Beijnen JH, Schellens JH. (2006). Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 27:17–24
   PubMed Web of Science ®Google Scholar
• Chandarlapaty S, Sawai A, Ye Q, et al. (2008). SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 14:240–8
   PubMed Web of Science ®Google Scholar
• Chen J, Lin H, Hu M. (2003). Metabolism of flavonoids via enteric recycling: role of intestinal disposition. J Pharmacol Exp Ther 304:1228–35
   PubMed Web of Science ®Google Scholar
• Chen L, Li Y, Yu H, et al. (2012). Computational models for predicting substrates or inhibitors of P-glycoprotein. Drug Discov Today 17:343–51
   PubMed Web of Science ®Google Scholar
• Fromm MF. (2000). P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 38:69–74
   PubMed Web of Science ®Google Scholar
• Fromm MF. (2003). Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Invest 33 Suppl 2:6–9
   Google Scholar
• Glaeser H. (2011). Importance of P-glycoprotein for drug-drug interactions. Handb Exp Pharmacol 201:285–97
   PubMedGoogle Scholar
• Goh LB, Spears KJ, Yao D, et al. (2002). Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem Pharmacol 64:1569–78
   PubMed Web of Science ®Google Scholar
• Gomez-Monterrey I, Sala M, Musella S, Campiglia P. (2012). Heat shock protein 90 inhibitors as therapeutic agents. Recent Pat Anticancer Drug Discov 7:313–36
   PubMed Web of Science ®Google Scholar
• Huang KH, Veal JM, Fadden RP, et al. (2009). Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem 52:4288–305
   PubMed Web of Science ®Google Scholar
• Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. (1993). In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 53:4595–602
   PubMed Web of Science ®Google Scholar
• Irvine JD, Takahashi L, Lockhart K, et al. (1999). MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 88:28–33
   PubMed Web of Science ®Google Scholar
• Jeong EJ, Liu Y, Lin H, Hu M. (2004) In situ single-pass perfused rat intestinal model for absorption and metabolism. In: Yan Z, Caldwell GW, eds. Methods in pharmacology and toxicology optimization in drug discovery: in vitro methods. Totowa: Humana Press Inc, 65–76
   Google Scholar
• Johnson DA, Amidon GL. (1988). Determination of intrinsic membrane transport parameters from perfused intestine experiments: a boundary layer approach to estimating the aqueous and unbiased membrane permeabilities. J Theor Biol 131:93–106
   PubMed Web of Science ®Google Scholar
• Jones HM, Houston JB. (2004). Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos 32:973–82
   PubMed Web of Science ®Google Scholar
• Liu H, Ma Z, Wu B. (2013). Structure-activity relationships and in silico models of P-glycoprotein (ABCB1) inhibitors. Xenobiotica 43:1018–26
   PubMed Web of Science ®Google Scholar
• Liu W, Liu H, Sun H, et al. (in press). Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS). Xenobiotica. [Epub ahead of print]. doi: 10.3109/00498254.2013.853849
   Google Scholar
• Madan J, Chawla G, Arora V, et al. (2005). Unbiased membrane permeability parameters for gabapentin using boundary layer approach. AAPS J 7:E224–30
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Swords R, Carew JS, et al. (2009). Targeting HSP90 for cancer therapy. Br J Cancer 100:1523–9
   PubMed Web of Science ®Google Scholar
• Miyata Y, Nakamoto H, Neckers L. (2013). The therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des 19:347–65
   PubMed Web of Science ®Google Scholar
• Okawa Y, Hideshima T, Steed P, et al. (2009). SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 113:846–55
   PubMed Web of Science ®Google Scholar
• Staud F, Ceckova M, Micuda S, Pavek P. (2010). Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics. Methods Mol Biol 596:199–222
   PubMedGoogle Scholar
• Tachibana T, Kato M, Takano J, Sugiyama Y. (2010). Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein. Curr Drug Metab 11:762–77
   PubMed Web of Science ®Google Scholar
• Tang F, Horie K, Borchardt RT. (2002). Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res 19:765–72
   PubMed Web of Science ®Google Scholar
• Tanigawara Y. (2000). Role of P-glycoprotein in drug disposition. Ther Drug Monit 22:137–40
   PubMed Web of Science ®Google Scholar
• Valenzuela B, Nácher A, Ruiz-Carretero P, et al. (2004). Profile of P-glycoprotein distribution in the rat and its possible influence on the salbutamol intestinal absorption process. J Pharm Sci 93:1641–8
   PubMed Web of Science ®Google Scholar
• Varma MV, Sateesh K, Panchagnula R. (2005). Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol Pharm 2:12–21
   PubMed Web of Science ®Google Scholar
• Volpe DA. (2011). Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. Future Med Chem 3:2063–77
   PubMed Web of Science ®Google Scholar
• Whitesell L, Lindquist SL. (2005). HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761–72
   PubMed Web of Science ®Google Scholar
• Xu H, Kulkarni KH, Singh R, et al. (2009). Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Mol Pharm 6:1703–15
   PubMed Web of Science ®Google Scholar
• Yang Z, Gao S, Wang J, et al. (2011). Enhancement of oral bioavailability of 20(S)-ginsenoside Rh2 through improved understanding of its absorption and efflux mechanisms. Drug Metab Dispos 39:1866–72
   PubMed Web of Science ®Google Scholar
• Ye L, Wang T, Tang L, et al. (2011). Poor oral bioavailability of a promising anticancer agent andrographolide is due to extensive metabolism and efflux by P-glycoprotein. J Pharm Sci 100:5007–17
   PubMed Web of Science ®Google Scholar